Mapping Cancer's evolution: a study to outsmart treatment resistance

NCT ID NCT05628376

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study follows 600 people with lung cancer or mesothelioma to track how their tumors evolve during and after treatment. Researchers collect blood, tissue, and imaging samples every few months to understand why some cancers come back or stop responding to therapy. The goal is to uncover patterns that could lead to smarter, more personalized treatments in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this could reveal why some lung cancers resist treatment or recur, pointing toward better therapies and personalized monitoring strategies.
What could go wrong
This is an observational study, not a treatment trial, so it will not directly benefit participants. Results may take years to translate into clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER (NON-SMALL CELL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University College London Hospitals NHS Foundation Trust

    RECRUITING

    London, NW1 2PG, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.